AstraZeneca's top products based on revenue 2022-2023
AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. As of 2023, AstraZeneca’s top pharmaceutical product by revenue was Farxiga, a medication used in the treatment of type 2 diabetes mellitus. During that year, Tagrisso generated around six billion U.S. dollars in revenue for the company. The second-highest revenue generator for AstraZeneca in was Tagrisso, while the COVID-19 vaccine, Vaxzevria, saw a huge decline from 1.8 billion dollars in 2022 to only 12 million dollars in 2023.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2023, the highest proportion of AstraZeneca’s employees was based in emerging markets. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2022, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2023, almost 25 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2023, AstraZeneca was projected to be among the world’s top six pharmaceutical companies according to the number of drugs they had under development at that time.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2023, the highest proportion of AstraZeneca’s employees was based in emerging markets. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2022, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2023, almost 25 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2023, AstraZeneca was projected to be among the world’s top six pharmaceutical companies according to the number of drugs they had under development at that time.
